EPISODE · Mar 14, 2022 · 11 MIN
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
from Urology Times Podcasts · host Urology Times
In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Amy D. Dobberfuhl, MD, MS, about the presentation, “Feasibility and efficacy of transvaginal onabotulinumtoxinA chemodenervation of the trigone for the third line treatment of refractory overactive bladder,” which was given at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Winter Meeting. Dobberfuhl is a urologist at Stanford Hospitals and Clinics and an assistant professor of urology at the Stanford University School of Medicine in California.
Embed this episode
What this episode covers
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
NOW PLAYING
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.